Clinical characteristics of 3062 COVID‐19 patients: A meta‐analysis

Abstract
Coronavirus disease 2019 (COVID‐19) has spread rapidly around the world since its emergence in humans last December. Previous studies suggested that numerous markers of inflammation were elevated in patients in with severe disease relative to patients with milder conditions, and an elevated level of interleukin‐6 (IL‐6) was associated with a high case fatality of COVID‐19 infection.
Funding Information
  • National Natural Science Foundation of China (81960343; the Emergency Science and Technology Brainstorm Project for the Prevention and Control of COVID‐19, which is part of the Guangxi Key Research and Development Plan, Grant/Award Number: AB20058002; and the High‐level Medical Expert Training Program of Guangxi“139”Plan Funding, Grant/Award Number: G201903027)